Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.

作者信息

Tantawy Shady I, Timofeeva Natalia, Hernandez Ana, Sarkar Aloke, Gandhi Varsha

出版信息

Oncotarget. 2023 Jun 21;14:653-655. doi: 10.18632/oncotarget.28440.

DOI:10.18632/oncotarget.28440

PMID:37343064

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10284423/

Abstract

摘要

相似文献

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.

Oncotarget. 2023 Jun 21;14:653-655. doi: 10.18632/oncotarget.28440.

Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.

Clin Cancer Res. 2023 Jan 17;29(2):446-457. doi: 10.1158/1078-0432.CCR-22-2088.

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.

Mol Cancer. 2014 Apr 30;13:98. doi: 10.1186/1476-4598-13-98.

AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.

Clin Cancer Res. 2020 Jul 15;26(14):3856-3867. doi: 10.1158/1078-0432.CCR-19-1397. Epub 2020 Jan 14.

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.

Int J Mol Sci. 2023 Apr 13;24(8):7180. doi: 10.3390/ijms24087180.

DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.

Cancer Biol Med. 2020 May 15;17(2):387-400. doi: 10.20892/j.issn.2095-3941.2019.0380.

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

Biomed Pharmacother. 2022 Oct;154:113546. doi: 10.1016/j.biopha.2022.113546. Epub 2022 Aug 18.

A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.

Pigment Cell Melanoma Res. 2015 Mar;28(2):161-70. doi: 10.1111/pcmr.12325. Epub 2014 Dec 18.

Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety.

Bioorg Chem. 2022 Oct;127:106018. doi: 10.1016/j.bioorg.2022.106018. Epub 2022 Jul 12.

Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.

Bioorg Chem. 2022 Apr;121:105643. doi: 10.1016/j.bioorg.2022.105643. Epub 2022 Jan 25.

引用本文的文献

Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies.

Int J Mol Sci. 2025 Oct 10;26(20):9859. doi: 10.3390/ijms26209859.

Eupatilin modulates the Mcl-1 ubiquitination status and PI3K/Akt/Foxo3a pathway to inhibit apoptosis and alleviate sepsis-induced acute myocardial injury.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 1. doi: 10.1007/s00210-025-04354-x.

Targeting MCL-1 protein to treat cancer: opportunities and challenges.

Front Oncol. 2023 Jul 31;13:1226289. doi: 10.3389/fonc.2023.1226289. eCollection 2023.

本文引用的文献

Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.

Clin Cancer Res. 2023 Jan 17;29(2):446-457. doi: 10.1158/1078-0432.CCR-22-2088.

AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.

Clin Cancer Res. 2020 Jul 15;26(14):3856-3867. doi: 10.1158/1078-0432.CCR-19-1397. Epub 2020 Jan 14.

Saga of Mcl-1: regulation from transcription to degradation.

Cell Death Differ. 2020 Feb;27(2):405-419. doi: 10.1038/s41418-019-0486-3. Epub 2020 Jan 6.

Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.

Trends Cell Biol. 2019 Jul;29(7):549-562. doi: 10.1016/j.tcb.2019.03.004. Epub 2019 Apr 25.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.

Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w.

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Blood. 2019 Feb 7;133(6):566-575. doi: 10.1182/blood-2018-07-865527. Epub 2018 Nov 29.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25.

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Cancer Discov. 2018 Dec;8(12):1566-1581. doi: 10.1158/2159-8290.CD-18-0140. Epub 2018 Sep 5.

The E3 ligase Mule protects the heart against oxidative stress and mitochondrial dysfunction through Myc-dependent inactivation of Pgc-1α and Pink1.

Sci Rep. 2017 Feb 2;7:41490. doi: 10.1038/srep41490.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验